Central Nervous System Neoplasms
"Central Nervous System Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Descriptor ID |
D016543
|
| MeSH Number(s) |
C04.588.614.250 C10.551.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Neoplasms".
This graph shows the total number of publications written about "Central Nervous System Neoplasms" by people in this website by year, and whether "Central Nervous System Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 3 | 0 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 4 | 0 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 0 | 3 |
| 2025 | 5 | 0 | 5 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Neoplasms" by people in Profiles.
-
A Report from the Inaugural Society of NeuroInterventional Surgery Neurointerventional Oncology Summit. AJNR Am J Neuroradiol. 2026 Jan 05; 47(1):1-8.
-
Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimics. Nat Commun. 2025 Sep 29; 16(1):8341.
-
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089.
-
Analytical Validation and Clinical Sensitivity of the Belay Summit Assay for the Detection of DNA Variants in Cerebrospinal Fluid of Primary and Metastatic Central Nervous System Cancer. J Mol Diagn. 2025 Jul; 27(7):615-629.
-
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Mar; 23(3):113-130.
-
Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. JAMA Oncol. 2025 Jan 01; 11(1):60-69.
-
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531.
-
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 07 09; 8(13):3507-3518.
-
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024 08; 99(8):1624-1627.
-
Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30600.